Announcements Trials

Browse Landscape

Phase

Status

Recruiting 4 Not yet recruiting 4 Active not recruiting 4 Terminated 3 Completed 3 Unknown 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Myeloproliferative Syndrome, Transient 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

Carboplatin 33 Pemetrexed 25 Cisplatin 23 Paclitaxel 20 Radiotherapy 16 Docetaxel 16 Gemcitabine 15 durvalumab 14 Radiosurgery 14 pembrolizumab 13 Nivolumab 13 Erlotinib Hydrochloride 10 Taxes 8 atezolizumab 7 Magnetic Resonance Spectroscopy 7 Drug Therapy 6 Cyclophosphamide 6 Bevacizumab 6 Platinum 5 Gefitinib 5 130-nm albumin-bound paclitaxel 5 Etoposide 4 Biopsy 4 Albumin-Bound Paclitaxel 4 1,2-diaminocyclohexaneplatinum II citrate 4 spartalizumab 3 sotorasib 3 poly ICLC 3 capmatinib 3 Surveys and Questionnaires 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma, Non-Small-Cell Lung × Observation × Clear all

NCT03770299 2022-03-24

CheckMate 9TN

Bristol-Myers Squibb

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡